Equities analysts expect BioLineRx (NASDAQ:BLRX) to announce ($0.07) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for BioLineRx’s earnings. BioLineRx posted earnings per share of ($0.08) during the same quarter last year, which suggests a positive year over year growth rate of 12.5%. The company is scheduled to issue its next earnings results before the market opens on Tuesday, May 22nd.
On average, analysts expect that BioLineRx will report full-year earnings of ($0.31) per share for the current fiscal year, with EPS estimates ranging from ($0.34) to ($0.28). For the next year, analysts anticipate that the firm will post earnings of ($0.33) per share, with EPS estimates ranging from ($0.37) to ($0.28). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover BioLineRx.
BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings data on Tuesday, March 6th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.01).
BioLineRx opened at $0.92 on Friday, Marketbeat reports. BioLineRx has a twelve month low of $0.85 and a twelve month high of $0.95. The stock has a market cap of $94.55 million, a PE ratio of -3.41 and a beta of 0.53.
A hedge fund recently raised its stake in BioLineRx stock. Renaissance Technologies LLC lifted its stake in BioLineRx (NASDAQ:BLRX) by 60.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 434,700 shares of the biotechnology company’s stock after purchasing an additional 164,500 shares during the quarter. Renaissance Technologies LLC owned 0.41% of BioLineRx worth $474,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 35.32% of the company’s stock.
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.